SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- April 17, 2007 -- Novacea, Inc. (NASDAQ: NOVC) today announced that the company’s product candidate, AQ4N, an investigational anti-cancer prodrug, was shown in a preclinical study to rapidly penetrate the hypoxic or oxygen-starved regions of tumors that are normally difficult to reach with conventional cancer therapies. Additionally, the study showed that when used in combination with mitoxantrone, a chemotherapeutic agent, tumor growth delay in rodent breast cancer models was achieved when compared to either agents used alone. Results from the study conducted at Princess Margaret Hospital at the University of Toronto were presented today at the American Association for Cancer Research (AACR) Annual Meeting in Los Angeles.
